RedHill Biopharma Ltd. (RDHL), a specialty biopharmaceutical company, has entered into an exclusive worldwide licensing agreement, excluding North America, with Liège, Belgium-based Hyloris Pharmaceuticals SA (HYL.BR) for its investigational drug RHB-102 or Bekinda.
This agreement allows Hyloris to develop and commercialize RHB-102 in various territories, with RedHill receiving an upfront payment, up to $60 million in milestone payments, and royalties on revenue.
RHB-102 is a once-daily, bimodal extended-release oral tablet formulation of Ondansetron, which is in advanced development for treating chemotherapy-induced nausea and vomiting, acute gastroenteritis, gastritis, and diarrhea-predominant irritable bowel syndrome or IBS-D.
The drug is expected to provide sustained relief from nausea and vomiting, with a potential breakthrough in oncology and post-surgical settings, where continuous symptom management is critical.
RHB-102 was found to be promising, with positive regulatory advice from the UK's Medicines and Healthcare products Regulatory Agency or MHRA signaling a clear pathway for a UK Marketing Authorization Application or MAA.
If approved, it could be the first oral, 24-hour extended-release Ondansetron for chemotherapy and radiotherapy-induced nausea and vomiting.
This agreement also follows RedHill's positive results from the U.S. Phase 2 study of RHB-102 for IBS-D and a Phase 3 study for gastroenteritis, both of which met their primary endpoints.
RDNT closed Monday's (Feb.24 2025) trading at $4.82 up by 1.26 percent. In premarket trading Tuesday the stock is down by 0.19 percent at $4.81 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.